Home » About us

ABOUT US

Flash BioSolutions is a leading Contract Development and Manufacturing Organization (CDMO) specializing in lentiviral vector manufacturing. We deliver high-quality viral vectors to support biotech companies in their transition from research to clinical phases.

A unique technical expertise in lentiviral manufacturing for two decades

Our comprehensive services span from discovery to clinical application, providing expert guidance and support throughout each project. We offer innovative RNA and DNA delivery solutions for a broad range of therapeutic fields, including gene addition, gene editing, and immunotherapy.

Our team of dedicated experts brings unparalleled passion and expertise to every project. With deep scientific knowledge and a commitment to innovation, our employees are the driving force behind our success. Their relentless pursuit of excellence and adherence to global GMP standards ensure that our clients receive the highest level of service and support.

Our commitment to flexibility, communication and collaboration with our customers is at the heart of what we do. Discover how our experience, dedication and the collective expertise of our passionate team can accelerate your therapeutic programmes from concept to clinical success.

HISTORY

With a rich history that has shaped our incredible expertise, Flash’s journey is testament to our unwavering commitment to innovation and excellence in therapeutic solutions. These are the milestones that have defined our progress towards becoming industry leaders.

2005

2011

2014

2015

2016

2017

2018

2019

2021

2022

2023

2024

2005

Creation of Vectalys: a world-leading company in the production of lentiviral solutions for Gene & Cell engineering

Set up in 2005 Vectalys multidisciplinary team has built a scientific and manufacturing platform dedicated to gene and cell engineering.

2011

First patents on the process of production & purification of lentiviral vectors

Vectalys has initially built its portfolio of patents on the quality of the lentiviral vector batches. The first two patent families are then respectively focused on the composition of the lentiviral batch and the resulting consequences on the target cells.

2014

Launch of standard product offers distributed worldwide by Clontech & Takara Bio

2015

Patent filling on LentiFlash® (FlashRNA®) technology

Vectalys develops a game-changing class of RNA carriers named LentiFlash®. A new generation of bacteriophage-driven RNA packaging system using Coat-retrovirus chimeras. First production of large-scale lentiviral batches (60ml) for a client conducting pre-clinical research programs.

2016

Creation of FlashCell, a spin-off of Vectalys

Vectalys as set up its unit, FlashCell and stayed focused on its manufacturing activity. Considering that safe & efficient delivery combined with manufacturing know-how is a therapeutic key of success, Vectalys has legitimately included therapeutic applications to its activities.

2017

Vectalys sub-licensed its new LentiFlash® technology and rights to the clinical-stage biotech company FlashCell

For a wide range of therapeutic applications including immunothery and gene editing approaches. In 2017, FlashCell carried out research programs to complete the intellectual portfolio and identify its own clinical programs.

2018

Creation of Flash Therapeutics, new leading CDMO for gene therapy

A result of the merger of Vectalys & FlashCell. Flash Therapeutics includes both a manufacturing platform and a new therapeutic gene therapy unit.

2019

GMP Platform at Meary Paris

First lentiviral vectors GMP batch from the Flash Therapeutics platform at Meary.

2021

Investments to become a leader in the biomanufacturing of DNA and RNA lentiviral technologies

15M€ financing agreement with TechLife Capital and Elaia Partners over 3 years to ensure the growth of its production capacities to industrial and clinical standards (GMP).

2022

Double the capacities of clinical manufacturing

▪ Flash Therapeutics announced to double its clinical batch production capacity by 2022 and expand to large-scale batch manufacturing starting 2023.
▪ Flash Therapeutics establishes its new biomanufacturing platform in Toulouse.

▪ Flash Therapeutics obtained a grant of €1.5M from the French government for the clinical manufacture of batches of LentiFlash® particles enabling the delivery of RNA as early as 2022 to manufacture a candidate RNA vaccine against COVID-19 by the end of 2022.
▪ Flash Therapeutics obtained a grant of €1M from the Occitanie Region to support the development of RNA/DNA technologies for gene transfer.

2023

Appointment of Jérôme Bédier as CEO of Flash Therapeutics

2024

Transformation into Flash BioSolutions to shine on the CDMO landscape.

Obtention of the Pharmaceutical Establishment status.

Previous Year

Next Year

Our mission

Learn about the core values and goals that drive Flash BioSolutions. Explore our Mission and Vision and see how we are shaping the future of therapeutic innovation.

Learn more

Governance

At our CDMO company, we pride ourselves on our diverse and highly skilled team of professionals who are dedicated to advancing pharmaceutical development and manufacturing.

Meet our team

Innovative Solutions

Discover the two cutting-edge technologies to cover all Cell & Gene Therapy applications, including vaccination.
If you need something else, don’t worry ! Tailor-made is in our DNA.

LentiCare®

Integrative lentiviral vector for a stable & long-term DNA transfer.

https://flashbiosolutions.com/lenticare-lentiviral-vector/

FlashRNA®

Innovative RNA vector for a fast & transient expression.
Non-integrating vector.

https://flashbiosolutions.com/flash-rna-delivery-technology/

Customized offer

Tailor-made particles to cover all your needs.

https://flashbiosolutions.com/technologies/other-technologies/

Case studies

Discover how Flash BioSolutions is transforming the field with real-world examples. Click here to explore our case studies and see our innovations in action.

See all the case studies

News

Keep up with the latest advancements, updates, and breakthroughs in our field. Click here to explore our news page and stay informed about our progress and innovations.

See all the news